Danske Bank A S Invests $39.63 Million in Axon Enterprise, Inc $AXON

Danske Bank A S bought a new stake in shares of Axon Enterprise, Inc (NASDAQ:AXON) during the 3rd quarter, HoldingsChannel reports. The institutional investor bought 55,220 shares of the biotechnology company’s stock, valued at approximately $39,628,000.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Vanguard Group Inc. lifted its holdings in shares of Axon Enterprise by 4.2% in the 3rd quarter. Vanguard Group Inc. now owns 9,314,164 shares of the biotechnology company’s stock worth $6,684,217,000 after acquiring an additional 376,904 shares during the last quarter. Jennison Associates LLC boosted its position in shares of Axon Enterprise by 53.8% during the third quarter. Jennison Associates LLC now owns 943,944 shares of the biotechnology company’s stock valued at $677,412,000 after buying an additional 330,213 shares during the period. Vestor Capital LLC boosted its position in shares of Axon Enterprise by 438,636.3% during the second quarter. Vestor Capital LLC now owns 833,599 shares of the biotechnology company’s stock valued at $690,170,000 after buying an additional 833,409 shares during the period. Norges Bank bought a new position in shares of Axon Enterprise during the second quarter valued at approximately $637,806,000. Finally, Northern Trust Corp grew its stake in shares of Axon Enterprise by 1.6% during the third quarter. Northern Trust Corp now owns 743,926 shares of the biotechnology company’s stock valued at $533,871,000 after buying an additional 11,726 shares during the last quarter. Hedge funds and other institutional investors own 79.08% of the company’s stock.

Axon Enterprise Stock Up 0.4%

Shares of NASDAQ AXON opened at $508.41 on Thursday. Axon Enterprise, Inc has a 52-week low of $396.41 and a 52-week high of $885.91. The firm has a market capitalization of $40.88 billion, a price-to-earnings ratio of 334.48, a PEG ratio of 10.81 and a beta of 1.46. The stock has a 50 day moving average price of $524.40 and a 200 day moving average price of $603.77. The company has a debt-to-equity ratio of 0.53, a quick ratio of 2.29 and a current ratio of 2.53.

Axon Enterprise (NASDAQ:AXON) last released its quarterly earnings data on Tuesday, February 24th. The biotechnology company reported $2.15 EPS for the quarter, topping the consensus estimate of $1.60 by $0.55. The company had revenue of $796.72 million for the quarter, compared to the consensus estimate of $755.29 million. Axon Enterprise had a return on equity of 2.82% and a net margin of 4.48%.Axon Enterprise’s quarterly revenue was up 38.5% on a year-over-year basis. During the same period last year, the business posted $2.08 EPS. Sell-side analysts expect that Axon Enterprise, Inc will post 5.8 earnings per share for the current year.

Axon Enterprise News Summary

Here are the key news stories impacting Axon Enterprise this week:

• Positive Sentiment: Stronger recurring revenue outlook — analysts and industry write-ups highlight that Axon’s Software & Services segment grew rapidly (~40% y/y in 2025), boosting subscriptions and recurring revenue visibility, which supports higher forward multiples. Axon’s Software & Services Strength in Focus
• Positive Sentiment: Ongoing municipal demand — recent local-government purchases/grants (Decatur $1.97M grant for DPD tech; Yavapai County approves Tasers funding) point to steady device and evidence-management adoption at the municipal level, supporting hardware + services revenue streams. Decatur grant article Yavapai County Tasers
• Positive Sentiment: Institutional interest noted — coverage/mentions (e.g., Baron Capital referenced in investor letters) signal investor interest from growth-focused funds, which can underpin demand for the stock. Baron Capital mention
• Neutral Sentiment: High retail/investor attention — multiple “trending” and comparative performance pieces are circulating, increasing short-term volume and volatility but not signaling a clear directional catalyst. Trending stock write-up
• Neutral Sentiment: Short-interest data appears unreliable — recent reports show “0 shares” and NaN changes, so there’s no actionable signal from the published short-interest figures; treat these data points cautiously.
• Negative Sentiment: Insider sale — Director Erika Nardini sold 198 shares (~$100k) and reduced her stake; while size is modest relative to market cap, insider sales can create short-term negative perception. SEC Form 4
• Negative Sentiment: Recent price weakness and skepticism — coverage (e.g., Forbes) documents a multi-day selloff and questions about whether Axon’s high-growth narrative has paused, which pressures near-term sentiment. Forbes analysis
• Negative Sentiment: Recent intraday/near-term pullbacks reported — some market write-ups note recent declines, adding to short-term volatility risk for momentum-driven holders. Yahoo Markets

Insider Transactions at Axon Enterprise

In related news, Director Erika Nardini sold 198 shares of the company’s stock in a transaction dated Tuesday, March 17th. The shares were sold at an average price of $506.58, for a total value of $100,302.84. Following the completion of the sale, the director directly owned 1,946 shares of the company’s stock, valued at $985,804.68. This represents a 9.24% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Patrick W. Smith sold 10,000 shares of the stock in a transaction dated Wednesday, February 25th. The stock was sold at an average price of $500.24, for a total transaction of $5,002,400.00. Following the transaction, the chief executive officer owned 3,090,997 shares in the company, valued at approximately $1,546,240,339.28. The trade was a 0.32% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 24,832 shares of company stock worth $13,903,398 over the last quarter. 4.40% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

AXON has been the subject of a number of research analyst reports. Robert W. Baird set a $800.00 price target on Axon Enterprise in a research note on Wednesday, February 25th. Royal Bank Of Canada cut their price objective on Axon Enterprise from $860.00 to $735.00 and set an “outperform” rating on the stock in a research report on Wednesday, February 25th. Barclays reduced their target price on Axon Enterprise from $702.00 to $682.00 and set an “overweight” rating on the stock in a research note on Wednesday, February 25th. Northcoast Research upgraded Axon Enterprise from a “neutral” rating to a “buy” rating and set a $742.00 target price for the company in a research report on Tuesday, January 6th. Finally, Craig Hallum reissued a “buy” rating and set a $820.00 target price on shares of Axon Enterprise in a research note on Wednesday, February 25th. Sixteen equities research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. Based on data from MarketBeat.com, Axon Enterprise currently has a consensus rating of “Moderate Buy” and a consensus target price of $762.93.

Axon Enterprise Company Profile

Axon Enterprise, Inc develops technology and weapons systems for public safety and law enforcement agencies, combining hardware, software and cloud services. The company’s hardware portfolio includes conducted energy weapons (commonly known as TASER devices), body-worn cameras and in-car camera systems. Axon pairs these devices with a suite of connected products and accessories designed to capture, store and manage field evidence.

Beyond hardware, Axon operates a subscription-based software platform for digital evidence management, evidence review and records management.